Category survey

Caring for people who have dementia in Community Hospitals: A longtitudal ethographic study of healthcare workers everyday decision making Investments < €500k United Kingdom 2016    

Balancing Best Interests in Medical Ethics and Law (BABEL). Investments < €500k United Kingdom 2016    

Biomarkers discovery in the progressive bulbar palsy/amyotrophic lateral sclerosis clinical spectrum: combined tissue and fluid-phase proteomics Investments < €500k United Kingdom 2016    

Regulation of the Heat Shock Response as a Treatment for Niemann-Pick type C disease Investments < €500k United Kingdom 2016    

A novel biomarker platform for dementia research with single molecule sensitivity. Investments < €500k United Kingdom 2016    

Narratives of diseased brains and failing minds: Dementia in science, medicine and literature in the twentieth century. Investments < €500k United Kingdom 2016    

Investigation into LRRK2 vesicular trafficking pathways to provide further insight into Parkinson’s disease pathogenesis. Investments < €500k United Kingdom 2016    

Estimating the benefits and harms of Z-drugs for people with dementia and sleep disorders Investments < €500k United Kingdom 2016    

The START (STrAtegies for RelaTives) study: a pragmatic randomised controlled trial to determine the effectiveness of a manual based coping strategy programme in promoting the mental health of carers of people with dementia – cohort follow-up Investments < €500k United…

Co-producing socio-technical solutions for people living with complex multi-morbidity: developing methodology and assessing pros and cons of a RCT Investments < €500k United Kingdom 2016    

Management of pain in people with dementia living in care homes: Programme and intervention development Investments < €500k United Kingdom 2016    

SERVED Memory: Feasibility study of Screening & Enhanced Risk management for Vascular Event related Decline in Memory Investments < €500k United Kingdom 2016    

Hypertension in Dementia – Feasibility Study Investments < €500k United Kingdom 2016    

The integration of biomedical research, describing the biological processes relevant to Parkinson’s, into the Gene Ontology database Investments < €500k United Kingdom 2016    

Modifing the exosomal release of alpha synuclein as a potential target to prevent disease progression in Parkinson’s Investments < €500k United Kingdom 2016    

Understanding the genome-wide gene expression landscape in Dementia with Lewy Bodies Investments < €500k United Kingdom 2016    

Glucocerebrosidase chaperones in Parkinson’s Investments < €500k United Kingdom 2016    

Characterisation of the long-term prognosis of Parkinson’s and development of statistical models to predict prognosis Investments < €500k United Kingdom 2016    

Screening a neuroactive drug library to identify new treatments for Parkinson’s Investments < €500k United Kingdom 2016    

The potential involvement of astrocytes in Parkinson’s: Investigation using human pluripotent stem cells Investments < €500k United Kingdom 2016    

The therapeutic potential for RVG9RÐp137 in a disease relevant model of Parkinson’s dementia Investments < €500k United Kingdom 2016    

Using a rapid diagnostic test for Parkinson’s disease to determine underlying mechanisms, develop new regenerative therapies and test the efficacy of existing regenerative therapies Investments < €500k United Kingdom 2016    

Structural analysis of the Parkinson’s associated kinase PINK1 Investments < €500k United Kingdom 2016    

Small molecules mimicking GDNF for regeneration of dopaminergic neurons in vivo Investments < €500k United Kingdom 2016    

Exploring novel neurostimulation based therapies for swallowing impairments in Parkinson’s Investments < €500k United Kingdom 2016    

Biomarkers of pain in Parkinson’s Investments < €500k United Kingdom 2016    

Understanding acetylcholine drive of striatal dopamine transmission in an animal model of Parkinson’s Investments < €500k United Kingdom 2016    

Mitochondrial function in sporadic Parkinson’s Investments < €500k United Kingdom 2016    

Glucocerebrosidase deficiency, alpha-synuclein and Parkinson’s: A zebrafish study Investments < €500k United Kingdom 2016    

Metabolic dysregulation in astrocytes derived from Parkin-mutant patients Investments < €500k United Kingdom 2016    

The effect of transcranial direct current stimulation on motor learning after stroke Investments < €500k United Kingdom 2016    

Does subcutaneous interleukin-1 receptor antagonist reduce inflammation after ischaemic stroke compared to placebo? Investments < €500k United Kingdom 2016    

Predicting Language Outcome and Recovery After Stroke (PLORAS) Investments < €500k United Kingdom 2016    

Practical management of cognitive and neuropsychiatric symptoms in MND – development of the MiNDToolkit Investments < €500k United Kingdom 2016    

Delivering personalised synthetic voices for patients with MND Investments < €500k United Kingdom 2016    

Determining the impact of a designated multidisciplinary care centre in Cambridge on the natural history of Motor Neurone Disease Investments < €500k United Kingdom 2016    

Whole genome methylomic profiling in Parkinson’s: An integrated genetic-epigenetic approach Investments < €500k United Kingdom 2016    

Are astrocytes required for optimal survival of ES cell-derived dopaminergic transplants? Investments < €500k United Kingdom 2016    

Testing a combination therapy with Ras-ERK and mTor inhibitors for L-DOPA induced dyskinesia Investments < €500k United Kingdom 2016    

Using shape memory scaffolds to increase transplant survival and prepare a nigro/striatal bridge Investments < €500k United Kingdom 2016    

Profiling post-translational modifications of histone proteins as a determinant of Parkinson’s susceptibility Investments < €500k United Kingdom 2016    

A pilot randomised controlled trial of a mindfulness based cognitive therapy delivered by Skype for people affected by Parkinson’s Investments < €500k United Kingdom 2016    

PD-HELP: Development of an intervention to increase help-seeking for non-motor symptoms in people with Parkinson’s Investments < €500k United Kingdom 2016    

Does prompt delivery of medication to in-patients with Parkinson’s decrease length of stay in hospital? Investments < €500k United Kingdom 2016    

Re-creating the basal ganglia circuitry in a dish: Towards a model for developing therapies for Parkinson’s Investments < €500k United Kingdom 2016    

The pilot clinical validation study of a novel pain scale for Parkinson’s Investments < €500k United Kingdom 2016    

Non-motor symptoms of people with Parkinson’s in black African/Caribbean and South Asian population in London: case control study and biomarkers and non-motor subtypes evaluation Investments < €500k United Kingdom 2016    

Alpha-synuclein and ER-mitochondria interactions in Parkinson’s Investments < €500k United Kingdom 2016    

Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation-PD (ICICLE-PD) Study Extension Investments < €500k United Kingdom 2016    

Predicting dementia in Parkinson’s: A genotypic and phenotypic study Investments < €500k United Kingdom 2016